v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as a single operating segment that is engaged in discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. A global research and development organization and a supply chain organization discover, develop, manufacture, and supply the Company’s products. A global commercial organization markets, distributes, and sells the products. The business is also supported by global corporate staff functions. The Company’s Chief Operating Decision Maker (the “CODM”) is the Chief Executive Officer, who assesses performance and allocates resources based on significant expenses and net income on a consolidated basis. The significant expenses that are regularly provided to the CODM include those amounts that are also reported on the consolidated statement of operations as well as below additional disaggregated measures. The CODM also reviews cash position (which includes cash and cash equivalents, current restricted cash, and short-term investments that are reported on the consolidated balance sheets) when making operating decisions. In accordance with ASC 280, the Company has only one reportable segment.
The following tables present disaggregated expenses that are regularly provided to the CODM:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Personnel compensation and related costs22,713 22,447 41,183 46,527 
Licensing fees15,000 — 37,000 19,997 
CROs/CMOs/Investigators expenses18,259 19,935 37,800 29,765 
Other costs5,794 8,232 11,374 15,054 
Total research and development expenses61,766 50,614 127,357 111,343 
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Clinical programs14,792 16,967 45,881 45,059 
Pre-Clinical programs19,609 5,069 31,325 8,383 
Unallocated research and development expenses27,365 28,578 50,151 57,901 
Total research and development expenses61,766 50,614 127,357 111,343 
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Personnel compensation and related costs44,707 42,679 85,767 83,322 
Other costs28,165 28,359 52,175 51,138 
Total selling, general, and administrative expenses72,872 71,038 137,942 134,460 
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Selling and marketing expenses51,556 46,764 94,994 88,703 
General and administrative expenses21,316 24,274 42,948 45,757 
Total selling, general, and administrative expenses72,872 71,038 137,942 134,460